Topic

Articles

Tufts CSDD study finds that acts of microaggression negatively impact psychological safety and performance.





Examining the Impact of Exclusionary Behaviors on Team Dynamics

Amidst difficulty in attracting underrepresented populations, industry is searching for ways to include more diverse datasets.


Data Equity: Representing Underrepresented Populations

Expanded offerings will increase Black representation in clinical trials, ensuring that new medicines are safe and effective for people of color.

Jumo Health Expands Health Equity Service Line

Director, Design Analytics, Applied Data Science Center, IQVIA

Survey examines trial enrollment motivation among diverse populations.

The Impact of Trial Design on Interest by Race and Ethnicity

Advancing responsible AI innovation to help resolve patient disparities.

Tackling Trial Diversity Through Higher Innovation Standards

Director, Patient Advocacy Strategy, ICON

Outlining new approaches and resources to help ignite progress in this area.

Strategies for Building Greater DE&I in Rare Disease Trials

Panel discussion at SCOPE highlights strategies to increase diversity in clinical trials.

Diversity Plans, Sharing for Meaningful Change

Vice President, Diversity, Equity, and Inclusion, Avantor

Senior Director, Global Customer Development, Clinical Services, Avantor

Regulatory compliance, collaboration, and effective use of technology among ways CROs can overcome challenges.

Considerations to Reach Underrepresented Groups

Norman M. Goldfarb is managing director of Elimar Systems, executive director of the Site Council, and executive director of the Clinical Research Interoperability Standards Initiative (CRISI).

Measuring different dimensions of diversity beforehand can lead to more thoughtful planning and execution.